Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
06 nov. 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year...
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
01 nov. 2023 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief...
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
31 oct. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on...
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
26 oct. 2023 08h00 HE
|
Myriad Genetics, Inc.
Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma...
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
28 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey...
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
19 sept. 2023 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic...
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
19 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social...
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
18 sept. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
06 sept. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine...
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
06 sept. 2023 07h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating...